var data={"title":"Tenofovir disoproxil fumarate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Tenofovir disoproxil fumarate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7019?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">see &quot;Tenofovir disoproxil fumarate: Drug information&quot;</a> and <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Tenofovir disoproxil fumarate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709065\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Post-treatment exacerbation of hepatitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe acute exacerbations of hepatitis have been reported in hepatitis B virus (HBV)-infected patients who have discontinued anti-hepatitis B therapy. Monitor hepatic function closely with clinical and laboratory follow-up for at least several months in patients who discontinue anti-hepatitis B therapy. If appropriate, resumption of anti-hepatitis B therapy may be warranted.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225434\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Viread</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855141\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Viread</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055611\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiretroviral Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HIV Agents (Anti-HIV Agents)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Nucleotide Reverse Transcriptase Inhibitor (NRTI)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055605\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">see &quot;Tenofovir disoproxil fumarate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents: <b>Note:</b> Some experts recommend avoiding tenofovir (especially for initial therapy) in prepubertal patients and those in early puberty (Sexual Maturity Rating stages 1 and 2), due to concerns about the potential increased risk of bone mineral density loss. Other experts recommend measuring bone mineral density (DXA) prior to initiation of therapy and every 6 to 12 months in these patients [HHS (pediatric) 2016]:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;2 years: Not approved for use; dose is unknown</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;12 years; weighing &lt;35 kg: Oral: 8 mg/kg/dose once daily; maximum daily dose: 300 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dosage form specific fixed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Oral powder: </i> <b>Note:</b> One level scoop = 40 mg tenofovir disoproxil fumarate</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">10 to &lt;12 kg: 80 mg (2 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">12 to &lt;14 kg: 100 mg (2.5 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">14 to &lt;17 kg: 120 mg (3 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">17 to &lt;19 kg: 140 mg (3.5 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">19 to &lt;22 kg: 160 mg (4 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">22 to &lt;24 kg: 180 mg (4.5 scoops)  once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">24 to &lt;27 kg: 200 mg (5 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">27 to &lt;29 kg: 220 mg (5.5 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">29 to &lt;32 kg: 240 mg (6 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">32 to &lt;34 kg: 260 mg (6.5 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">34 to &lt;35 kg: 280 mg (7 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;35 kg: 300 mg (7.5 scoops) once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Oral tablets:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">17 to &lt;22 kg: 150 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">22 to &lt;28 kg: 200 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">28 to &lt;35 kg: 250 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">&ge;35 kg: 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents; weight &ge;35 kg: Oral: 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>HIV-1 nonoccupational postexposure prophylaxis (nPEP)</b> (HHS [nPEP] 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;2 years: Oral: Age- and weight-appropriate dosing (see HIV-1 infection, treatment above) for 28 days in combination with other antiretroviral agents. Initiate therapy within 72 hours of exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: The combination product is recommended [see emtricitabine and tenofovir disoproxil fumarate monograph]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatitis B infection, chronic:</b> Children and Adolescents &ge;12 years weighing &ge;35 kg: Oral: 300 mg once daily; <b>Note:</b> Optimal duration of therapy is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>HIV-1 infection, treatment:</b> Oral: 300 mg once daily; <b>Note:</b> Use in combination with other antiretroviral agents</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Hepatitis B infection, chronic:</b> Oral: 300 mg once daily; <b>Note:</b> Tenofovir is recommended for first-line treatment of HBV (AASLD [Lok 2009]). Concurrent use with adefovir and/or tenofovir combination products should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Treatment duration (AASLD practice guidelines [Lok 2009]):</i> <b> Note:</b> Patients not achieving &lt;2 log decrease in serum HBV DNA after at least 6 months of therapy should either receive additional treatment or be switched to an alternative therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Hepatitis Be antigen (HBeAg) positive chronic hepatitis: Treat &ge;1 year until HBeAg seroconversion and undetectable serum HBV DNA; continue therapy for &ge;6 months after HBeAg seroconversion</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">HBeAg negative chronic hepatitis: Treat &gt;1 year until hepatitis B surface antigen (HB<sub>s</sub>Ag) clearance</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Decompensated liver disease: Lifelong treatment is recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children &ge;2 years and Adolescents: There are no dosage adjustments provided in manufacturer's labeling; has not been studied. Dosage should be decreased in patients with CrCl &lt;50 mL/minute (HHS [pediatric] 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\"> Adult: <b>Note:</b> Use of powder formulation has not been evaluated in renal impairment. Closely monitor clinical response and renal function in these patients; clinical effectiveness and safety of these guidelines have not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &ge;50 mL/minute: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 30 to 49 mL/minute: 300 mg every 48 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl 10 to 29 mL/minute: 300 mg every 72 to 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">CrCl &lt;10 mL/minute without dialysis: There are no dosage adjustments provided in manufacturer&rsquo;s labeling; has not been studied.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hemodialysis: 4 hours of hemodialysis removed ~10% of a single 300 mg dose; 300 mg every 7 days or after a total of ~12 hours of dialysis (eg, once weekly with 3 hemodialysis sessions of ~4 hours in length); administer dose after completion of dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Children &ge;2 years, Adolescents, and Adults: No dosage adjustment required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225410\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, Oral, as disoproxil fumarate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viread: 40 mg/g (60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as disoproxil fumarate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viread: 150 mg, 200 mg, 250 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Viread: 300 mg [contains fd&amp;c blue #2 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225396\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055615\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder: Must administer with food. Measure dose only using the supplied dosing scoop. Mix powder well with 2-4 ounces of soft food (applesauce, baby food, yogurt) and swallow immediately (avoids bitter taste); ensure that entire mixture is ingested. Do <b>not</b> mix in liquid (powder may float on top of the liquid even after stirring).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: May be administered without regard to meals. Do not crush oral tablets (DHHS [pediatric] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225429\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions are permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Dispense only in original container.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055614\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages &ge;2 years and adults); <b>Note:</b> HIV regimens consisting of three antiretroviral agents are strongly recommended; treatment of chronic hepatitis B virus (HBV) (FDA approved in ages &ge;12 years and adults). Has also been used for HIV-1 nonoccupational postexposure prophylaxis (nPEP).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25708072\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225459\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Includes data from both treatment-naive and treatment-experienced HIV patients and in chronic hepatitis B.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Cardiovascular: Chest pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, depression, dizziness, fatigue, headache, insomnia, pain, peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis, pruritus, skin rash (includes maculopapular, pustular, or vesiculobullous rash; pruritus; or urticaria)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Glycosuria, hypercholesterolemia, hyperglycemia, increased serum triglycerides, lipodystrophy, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, dyspepsia, flatulence, increased serum amylase, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Neutropenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT, increased serum AST, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, decreased bone mineral density, increased creatine phosphokinase, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasopharyngitis, pneumonia, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Angioedema, exacerbation of hepatitis B (following discontinuation), Fanconi&rsquo;s syndrome, hepatitis, hypersensitivity reaction, hypokalemia, hypophosphatemia, immune reconstitution syndrome, increased gamma-glutamyl transferase, interstitial nephritis, lactic acidosis, myopathy, nephrogenic diabetes insipidus, nephrotoxicity, osteomalacia, pancreatitis, polyuria, proteinuria, proximal tubular nephropathy, renal insufficiency, renal tubular necrosis, rhabdomyolysis, severe hepatomegaly with steatosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225416\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Hypersensitivity to tenofovir or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225400\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone mineral density: In clinical trials, use has been associated with decreases in bone mineral density in HIV-1 infected adults and increases in bone metabolism markers. Serum parathyroid hormone and 1,25 vitamin D levels were also higher. Decreases in bone mineral density have also been observed in clinical trials of HIV-1 infected pediatric patients. Observations in chronic hepatitis B infected pediatric patients (aged 12-18 years) were similar. In all pediatric clinical trials, skeletal growth (height) appears unaffected. Consider monitoring of bone density in adult and pediatric patients with a history of pathologic fractures or with other risk factors for bone loss or osteoporosis. Consider calcium and vitamin D supplementation for all patients; effect of supplementation has not been studied but may be beneficial. Long-term bone health and fracture risk unknown. If abnormalities are suspected, expert assessment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactic acidosis/hepatomegaly: Lactic acidosis and severe hepatomegaly with steatosis, sometimes fatal, have been reported with the use of nucleoside analogs, alone or in combination with other antiretrovirals. Suspend treatment in any patient who develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity (marked transaminase elevation may/may not accompany hepatomegaly and steatosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Osteomalacia and renal dysfunction: May cause osteomalacia with proximal renal tubulopathy. Bone pain, extremity pain, fractures, arthralgias, weakness and muscle pain have been reported. In patients at risk for renal dysfunction, persistent or worsening bone or muscle symptoms should be evaluated for hypophosphatemia and osteomalacia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: May cause renal toxicity (acute renal failure and/or Fanconi syndrome); avoid use with concurrent or recent nephrotoxic therapy (including high dose or multiple NSAID use). Acute renal failure has occurred in HIV-infected patients with risk factors for renal impairment who were on a stable tenofovir regimen to which a high dose or multiple NSAID therapy was added. Consider alternatives to NSAIDS in patients taking tenofovir disoproxil fumarate and at risk for renal impairment. Calculate estimated creatinine clearance prior to initiation of therapy and as clinically appropriate during therapy. In patients at risk for renal dysfunction, including patients who have experienced renal events while taking adefovir, also assess serum phosphorus, urine glucose, and urine protein prior to and periodically during treatment. Dosage adjustment required in patients with CrCl &lt;50 mL/minute. IDSA guidelines recommend discontinuing tenofovir (and substituting with alternative antiretroviral therapy) in HIV-infected patients who develop a decline in GFR (a &gt;25% decrease in GFR from baseline and to a level of &lt;60 mL/minute/1.73 m<sup>2</sup>) during use, particularly in presence of proximal tubular dysfunction (eg, euglycemic glycosuria, increased urinary phosphorus excretion and hypophosphatemia, proteinuria [new onset or worsening]) (IDSA [Lucas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic hepatitis B: <b>[US Boxed Warning]: Severe, acute exacerbation of hepatitis B may occur upon discontinuation.</b> <b>Monitor liver function several months after discontinuing treatment; reinitiation of antihepatitis B therapy may be required.</b> Treatment of HBV in patients with unrecognized/untreated HIV may lead to HIV resistance; patients should be tested for presence of HIV infection prior to initiating therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Limited data supporting treatment of chronic hepatitis B in patients with decompensated liver disease; observe for increased adverse reactions, including renal dysfunction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Tenofovir is predominately eliminated renally. Use with caution in patients with renal impairment (CrCl &lt;50 mL/minute); dosage adjustment required. IDSA guidelines recommend avoiding tenofovir in HIV patients with preexisting kidney disease (CrCl &lt;50 mL/minute and not on hemodialysis or GFR &lt;60 mL/minute/1.73 m<sup>2</sup>) when other effective HIV treatment options exist because data suggest risk of chronic kidney disease (CKD) is increased (IDSA [Lucas 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concomitant therapy: Do not use in combination with other tenofovir disoproxil fumarate or tenofovir alafenamide products, or with adefovir.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Hepatitis B coinfection: Treatment of HBV with tenofovir monotherapy in patients with unrecognized/untreated HIV may lead to rapid HIV resistance. Patients should be tested for coinfection prior to initiation of therapy. In patients coinfected with HIV and HBV, an appropriate antiretroviral combination should be selected due to HIV resistance potential; these patients should receive tenofovir dosed for HIV therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: HIV treatment: Do not use as monotherapy in treatment of HIV. Clinical trials in HIV-infected patients whose regimens contained only three nucleoside reverse transcriptase inhibitors (NRTI) show less efficacy, early virologic failure and high rates of resistance substitutions. Use three NRTI regimens with caution and monitor response carefully. Triple drug regimens with two NRTIs in combination with a non-nucleoside reverse transcriptase inhibitor or a HIV-1 protease inhibitor are usually more effective.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25952660\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Osteomalacia and reduced bone mineral density (BMD) may occur; long-term effects in humans are not known. Postmarketing cases of osteomalacia which may increase risk of bone fractures have also been reported in association with proximal renal tubulopathy. Recent studies suggest that tenofovir-related bone loss may be greater in children who are less mature (eg, Tanner stage 1 to 2) than in those who are more physically mature (Tanner &ge;3). A significant decrease in lumbar spine BMD (&gt;6%) was reported in five of 15 pediatric patients who received a tenofovir-containing regimen for 48 weeks. No orthopedic fractures occurred, but two patients required discontinuation of tenofovir. All five patients with a decrease in BMD were virologic responders and prepubertal (Tanner Stage 1). This study found a moderately strong correlation between decreases in bone mineral density z scores at week 48 and age at baseline. No correlation between decreases in bone mineral density z scores and tenofovir dose or pharmacokinetics was observed; BMD loss may limit the usefulness of tenofovir in prepubertal children [Giacomet 2005; Hazra 2005; Purdy 2008]. <b>Note:</b> The sexual maturity rating (SMR) has replaced Tanner staging to identify puberty stages in adolescent patients (HHS [pediatric] 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225448\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, P-glycoprotein/ABCB1; <b>Inhibits</b> MRP2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225404\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12824&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acyclovir-Valacyclovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Acyclovir-Valacyclovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adefovir: May diminish the therapeutic effect of Tenofovir Products. Adefovir may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Adefovir.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Atazanavir. Atazanavir may increase the serum concentration of Tenofovir Disoproxil Fumarate.  Management: Must use ritonavir-boosting in adults; give combo (atazanavir/ritonavir 300mg/100mg and tenofovir 300mg) as a single daily dose with food.  Pediatric patients, pregnant patients, and users of H2-blockers require other dose changes.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cidofovir: May increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Cidofovir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May enhance the adverse/toxic effect of Tenofovir Products. More specifically, cobicistat may impair proper tenofovir monitoring and dosing.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: Tenofovir Disoproxil Fumarate may increase the serum concentration of Darunavir. Darunavir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to this combination whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Didanosine: Tenofovir Disoproxil Fumarate may diminish the therapeutic effect of Didanosine. Tenofovir Disoproxil Fumarate may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir disoproxil fumarate and didanosine.  Consider altering even existing, stable treatment to avoid this combination.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: Tenofovir Products may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: May increase the serum concentration of Tenofovir Disoproxil Fumarate. Management: Avoidance of this combination is recommended under some circumstances.  Refer to full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May enhance the nephrotoxic effect of Tenofovir Disoproxil Fumarate. Lopinavir may increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the nephrotoxic effect of Tenofovir Products. Management: Seek alternatives to these combinations whenever possible.  Avoid use of tenofovir with multiple NSAIDs or any NSAID given at a high dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: Tenofovir Disoproxil Fumarate may decrease the serum concentration of Tipranavir. Tipranavir may decrease the serum concentration of Tenofovir Disoproxil Fumarate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: May increase the serum concentration of Tenofovir Disoproxil Fumarate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225430\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Fatty meals may increase the bioavailability of tenofovir. Management: May administer with or without food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225406\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225420\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Tenofovir has a high level of transfer across the human placenta following maternal use of tenofovir disoproxil fumarate. No increased risk of overall birth defects has been observed following first trimester exposure according to data collected by the antiretroviral pregnancy registry. Maternal antiretroviral therapy (ART) may increase the risk of preterm delivery, although available information is conflicting possibly due to variability of maternal factors (disease severity; gestational age at initiation of therapy); however, maternal antiretroviral medication should not be withheld due to concerns of preterm birth. Intrauterine growth has not been affected following use of tenofovir disoproxil fumarate, but data are conflicting about potential growth effects later in infancy. Clinical studies in children have shown bone demineralization with chronic use. Bone mineral content was also decreased in infants following in utero exposure. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children who develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential mitochondrial dysfunction. Cases of lactic acidosis and hepatic steatosis related to mitochondrial toxicity have been reported with use of nucleoside reverse transcriptase inhibitors (NRTIs). These adverse events are similar to other rare but life-threatening syndromes that occur during pregnancy (eg, HELLP syndrome). In general NRTIs are well tolerated and the benefits of use generally outweigh potential risk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Health and Human Services (HHS) Perinatal HIV Guidelines consider tenofovir disoproxil fumarate a component in preferred regimens for initial therapy in antiretroviral-na&iuml;ve pregnant females. The guidelines also consider emtricitabine plus tenofovir disoproxil fumarate, or lamivudine plus tenofovir disoproxil fumarate as recommended dual NRTI backbone for HIV/HBV coinfected pregnant females. Hepatitis B flare may occur if tenofovir disoproxil fumarate is discontinued. Tenofovir disoproxil fumarate is also a recommended component of a regimen when acute HIV infection is detected during pregnancy. Limited data indicate decreased maternal exposure during the third trimester; dose adjustments are not needed.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, ART is recommended for all pregnant females with HIV to keep the viral load below the limit of detection and reduce the risk of perinatal transmission. When HIV is diagnosed during pregnancy in a female who has never received antiretroviral therapy, ART should begin as soon as possible after diagnosis. Females who become pregnant on a stable ART regimen may continue that regimen if viral suppression is effective, appropriate drug exposure can be achieved, contraindications for use in pregnancy are not present, and the regimen is well tolerated. Monitoring during pregnancy is more frequent than in nonpregnant adults; ART should be continued postpartum for all females living with HIV.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Tenofovir disoproxil fumarate is one of the agents recommended for pre-exposure prophylaxis in couples with differing HIV status who are planning a pregnancy. The partner without HIV should begin therapy 1 month prior to attempting conception and continue therapy for 1 month after attempting conception.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In hepatitis B-infected women (not coinfected with HIV), the AASLD chronic hepatitis B treatment guidelines suggest antiviral therapy to reduce the risk of perinatal transmission of hepatitis B in HBsAg-positive pregnant women with an HBV DNA &gt;200,000 units/mL. There are limited data on the level of HBV DNA for when antiviral therapy is routinely recommended (&gt;200,000 units/mL is a conservative recommendation); however, the AASLD recommends against antiviral therapy to reduce the risk of perinatal transmission in HBsAg-positive pregnant women with an HBV DNA &le;200,000 units/mL. Tenofovir is one of the antivirals that has been studied in pregnant women (and may be the preferred agent); with most studies initiating antiviral therapy at 28 to 32 weeks gestation and discontinuing antiviral therapy between birth to 3 months postpartum (monitor for ALT flares every 3 months for 6 months following discontinuation). There is insufficient long-term safety data in infants born to mothers who took antiviral agents during pregnancy (AASLD [Terrault 2016]),</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Health care providers are encouraged to enroll pregnant females exposed to antiretroviral medications as early in pregnancy as possible in the Antiretroviral Pregnancy Registry (1-800-258-4263 or http://www.APRegistry.com). Health care providers caring for HIV-infected females and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1055610\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hepatitis B, treatment:</b> Test patients for HIV prior to starting therapy; CBC with differential, hemoglobin, MCV, reticulocyte count, liver enzymes, bilirubin, renal and hepatic function tests, and HBV RNA plasma levels. Monitor for potential bone and renal abnormalities. Calculate creatinine clearance in all patients prior to starting tenofovir therapy and as clinically needed; monitor for alterations in calculated creatinine clearance and serum phosphorus in patients at risk or with a history of renal dysfunction and patients receiving concurrent nephrotoxic agents. Monitor weight and growth in children. Consider bone mineral density assessment for all patients with a history of pathologic bone fractures or other risk factors for osteoporosis or bone loss. Monitor hepatic function closely (clinically and with laboratory tests) for at least several months after discontinuing tenofovir therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>HIV treatment: Note:</b> The absolute CD4 cell count is currently recommended to monitor immune status in children of all ages; CD4 percentage can be used as an alternative in children &lt;5 years of age. This recommendation is based on the use of absolute CD4 cell counts in the current pediatric HIV infection stage classification and as thresholds for urgency of initiation of antiretroviral treatment (HHS [pediatric] 2017). Screen for hepatitis B before starting tenofovir. Also prior to initiation of therapy: Genotypic resistance testing, CD4 and viral load (every 3 to 4 months), CBC with differential, LFTs, BUN, creatinine, urine dipstick for protein and glucose, electrolytes, and glucose, urinalysis (every 6 to 12 months), and assessment of readiness for adherence with medication regimen. At initiation and with any change in treatment regimen: Hepatitis B screening (at change in therapy in patients who previously demonstrated no immunity to hepatitis B), CBC with differential, electrolytes, calcium, phosphate, glucose, LFTs, bilirubin, urinalysis (at initiation), BUN, creatinine, albumin, total protein, lipid panel (at initiation), CD4, and viral load. After 1 to 2 weeks of therapy: Signs of medication toxicity and adherence. After 2 to 4 weeks of therapy: CBC with differential, viral load, and signs of medication toxicity, and adherence; then every 3 to 4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, viral load, signs of medication toxicity, and adherence. Every 6 to 12 months: Lipid panel and urinalysis. CD4 monitoring frequency may be decreased to every 6 to 12 months in children who are adherent to therapy if the value is well above the threshold for opportunistic infections, viral suppression is sustained, and the clinical status is stable for more than 2 to 3 years. In patients with known or suspected complex drug resistance patterns, phenotypic resistance testing (usually in addition to genotypic resistance testing) should be performed (HHS [pediatric] 2017). Monitor for growth and development, signs of HIV-specific physical conditions, HIV disease progression, opportunistic infections, bone loss, or lactic acidosis. Consider bone mineral density assessment for all patients with a history of pathologic bone fractures or other risk factors for osteoporosis or bone loss. Some experts recommend obtaining a DXA scan prior to therapy and every 6 to 12 months during therapy for patients in pre- and early puberty (Sexual Maturity Rating stages 1 and 2) (HHS [pediatric] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225399\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Tenofovir disoproxil fumarate (TDF), a nucleotide reverse transcriptase inhibitor, is an analog of adenosine 5'-monophosphate; it interferes with the HIV viral RNA dependent DNA polymerase resulting in inhibition of viral replication. TDF is first converted intracellularly by hydrolysis to tenofovir and subsequently phosphorylated to the active tenofovir diphosphate. Tenofovir inhibits replication of HBV by inhibiting HBV polymerase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225415\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 1.2 to 1.3 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &lt;7% to serum proteins </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Tenofovir disoproxil fumarate (TDF) is converted intracellularly by hydrolysis (by non-CYP enzymes) to tenofovir, then phosphorylated to the active tenofovir diphosphate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Tablets: ~25% (fasting); increases ~40% with high-fat meal </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Powder: Peak serum concentrations are 26% lower compared to tablet, but the mean AUCs are similar</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Serum: 17 hours; intracellular: 10 to 50 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Fasting: 36 to 84 minutes; With high-fat meal: 96 to 144 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (70% to 80%) via filtration and active secretion, primarily as unchanged tenofovir within 72 hours; after multiple oral doses (administered with food): 32% &plusmn; 10% is excreted in the urine within 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Total body clearance is decreased in patients with renal impairment </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225419\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Powder</b> (Viread Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/g (60 g): $746.06</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Tenofovir Disoproxil Fumarate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $1,215.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Viread Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $1,268.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg (30): $1,268.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (30): $1,268.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (30): $1,368.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855142\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Agifovir (VN);</li>\n      <li>Dipovir (BD);</li>\n      <li>Foviral (BD);</li>\n      <li>Glonovir (VN);</li>\n      <li>Ricovir (ID, TH, ZW);</li>\n      <li>Tenof (TH, UA, ZW);</li>\n      <li>Tenofir (CO);</li>\n      <li>Tenofo-B (PH);</li>\n      <li>Tenohop (UA);</li>\n      <li>Tenolam (ET);</li>\n      <li>Tenozet (JP);</li>\n      <li>Tenvir (ET, LK, UA);</li>\n      <li>Tenvira (BD);</li>\n      <li>Tenvor (LB);</li>\n      <li>Viraday (ET);</li>\n      <li>Viread (AE, AR, AT, AU, BB, BE, BG, BR, CH, CL, CN, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HK, HN, HR, HU, IE, IL, IS, IT, KR, KW, LT, LU, LV, MT, MX, NI, NL, NO, NZ, PA, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, SV, TH, TR, TW, UA, UY, VN, ZW);</li>\n      <li>Xynovir (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, Department of Health and Human Services. April 8, 2015. Available at <a href=\"http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf\" target=\"_blank\">http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. April 2017. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">https://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf</a>. Accessed November 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Updated guidelines for antiretroviroal postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV &minus; United States, 2016. Available at <a href=\"https://stacks.cdc.gov/view/cdc/38856\" target=\"_blank\">https://stacks.cdc.gov/view/cdc/38856</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Giacomet V, Mora S, Martelli L, Merlo M, Sciannamblo M, Vigan&ograve; A. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. <i>J Acquir Immune Defic Syndr</i>. 2005;40(4):448-450.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/16280700/pubmed\" target=\"_blank\" id=\"16280700\">16280700</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazra R, Balis FM, Tullio AN, et al, &ldquo;Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children,&rdquo; <i>Antimicrob Agents Chemother</i>, 2004, 48(1):124-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/14693529/pubmed\" target=\"_blank\" id=\"14693529\">14693529</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. <i>Pediatrics</i>. 2005;116(6):e846-e854.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/16291735/pubmed\" target=\"_blank\" id=\"16291735\">16291735</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009. Available at http://www.aasld.org/practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/Chronic_Hep_B_Update_2009%208_24_2009.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(9):e96-e138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/25234519/pubmed\" target=\"_blank\" id=\"25234519\">25234519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lyseng-Williamson KA, Reynolds NA, Plosker GL. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. <i>Drugs</i>. 2005;65(3):413-432.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/15669881/pubmed\" target=\"_blank\" id=\"15669881\">15669881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Public Health Agency of Canada (PHAC), Canadian Guidelines on Sexually Transmitted Infection. Available at http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php. Last modified December 2013. Accessed December 30, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. <i>J Pediatr</i>. 2008;152(4):582-584.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/tenofovir-disoproxil-fumarate-pediatric-drug-information/abstract-text/18346519/pubmed\" target=\"_blank\" id=\"18346519\">18346519</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Viread (tenofovir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; February 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12824 Version 171.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709065\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F225434\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855141\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1055611\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1055605\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F225410\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F225396\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1055615\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F225429\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1055614\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F25708072\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F225459\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F225416\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F225400\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25952660\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F225448\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F225404\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F225430\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F225406\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F225420\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1055610\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F225399\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F225415\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F225419\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F855142\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12824|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-drug-information\" class=\"drug drug_general\">Tenofovir disoproxil fumarate: Drug information</a></li><li><a href=\"topic.htm?path=tenofovir-disoproxil-fumarate-patient-drug-information\" class=\"drug drug_patient\">Tenofovir disoproxil fumarate: Patient drug information</a></li></ul></div></div>","javascript":null}